Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Stratified DCEG/DCAG therapy vs decitabine monotherapy in MDS/sAML based on TP53 mutation
ChiCTR2000035447Phase 4Recruiting
- Sponsor
- Huadong Hospital, Fudan University
- Start
- Aug 2020
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised trial of decitabine, etoposide, cytarabine and granulocyte colony-stimulating factor in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) (2 arms), sponsored by Huadong Hospital, Fudan University. Primary endpoints: Routine blood test, Bone marrow cytologic examination and 1 more. Started Aug 2020; status: recruiting.
02
Drugs
decitabineetoposidecytarabinegranulocyte colony-stimulating factor
03
Conditions
myelodysplastic syndrome (MDS)acute myeloid leukemia (AML)
Beyond the preview
Go deeper on ChiCTR2000035447.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000035447.